HomeAboutRankingsData Sources
ยฉ 2026 GeneE
๐Ÿงฌ
GeneE
25 sources retrieved ยท Most recent: April 2026 ยท Index updated 15 days ago
โ“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
GABRG2
gamma-aminobutyric acid type A receptor subunit gamma2
Chromosome 5 ยท 5q34
NCBI Gene: 2566Ensembl: ENSG00000113327.17HGNC: HGNC:4087UniProt: A0A1W2PQR9
172PubMed Papers
24Diseases
74Drugs
127Pathogenic Variants
FUNCTIONAL ROLE
Ion ChannelTransporter
RESEARCH IMPACT
TrendingVariant-Rich
CLINICAL
FDA Approved TargetOMIM Disease Gene
DATA QUALITY
โœ“ Experimental GO Evidenceโœ“ Swiss-Prot Reviewed
protein bindinggamma-aminobutyric acid signaling pathwayGABA-A receptor activitychloride transmembrane transportGeneralized epilepsy with febrile seizures-pluschildhood absence epilepsySeizureepilepsy
โœฆAI Summary

GABRG2 encodes the gamma-2 subunit of GABAA receptors, heteropentameric ligand-gated chloride channels that mediate inhibitory neurotransmission in the brain 1. The gamma-2 subunit is essential for receptor trafficking and synaptic localization, playing a critical role in both synaptic and extrasynaptic GABAergic signaling 1. When activated by GABA, these receptors allow chloride influx, hyperpolarizing neurons and reducing their excitability 1. GABRG2 variants are strongly associated with epilepsy syndromes, particularly genetic epilepsy with febrile seizures plus (GEFS+), developmental and epileptic encephalopathy, and generalized epilepsy 23. The C588T polymorphism increases genetic generalized epilepsy risk, particularly in Asian populations 4. Functional studies reveal that GABRG2 mutations can cause both gain-of-function and loss-of-function effects, with transmembrane domain variants typically associated with more severe phenotypes 15. Neuroimaging studies in GABRG2 variant carriers show altered functional connectivity in somatosensory cortex and striatothalamic networks 6. The protein interacts with approved antiepileptic drugs, suggesting potential therapeutic targeting opportunities 4.

Sources cited
1
GABRG2 encodes gamma-2 subunit of GABAA receptors and is associated with variable epilepsy phenotypes
PMID: 35718920
2
GABRG2 shows significant burden of de novo mutations in neurodevelopmental disorders
PMID: 33004838
3
GABRG2 mutations are associated with GEFS+ and various epilepsy syndromes
PMID: 39143639
4
C588T polymorphism increases epilepsy risk and GABRG2 interacts with antiepileptic drugs
PMID: 33650258
5
GABRG2 variants can cause both gain-of-function and loss-of-function effects
PMID: 39642202
6
GABRG2 variants show altered brain connectivity patterns in neuroimaging studies
PMID: 31321301
Disease Associationsโ“˜24
Generalized epilepsy with febrile seizures-plusOpen Targets
0.83Strong
childhood absence epilepsyOpen Targets
0.77Strong
SeizureOpen Targets
0.72Strong
epilepsyOpen Targets
0.72Strong
genetic developmental and epileptic encephalopathyOpen Targets
0.66Moderate
Lennox-Gastaut syndromeOpen Targets
0.64Moderate
major depressive disorderOpen Targets
0.62Moderate
insomniaOpen Targets
0.61Moderate
migraine disorderOpen Targets
0.61Moderate
panic disorderOpen Targets
0.60Moderate
anxiety disorderOpen Targets
0.60Moderate
AgitationOpen Targets
0.60Moderate
AnxietyOpen Targets
0.60Moderate
alcohol dependenceOpen Targets
0.60Moderate
postpartum depressionOpen Targets
0.58Moderate
PainOpen Targets
0.57Moderate
status epilepticusOpen Targets
0.57Moderate
generalized anxiety disorderOpen Targets
0.56Moderate
HeadacheOpen Targets
0.55Moderate
Rolandic epilepsyOpen Targets
0.55Moderate
Developmental and epileptic encephalopathy 74UniProt
Epilepsy, childhood absence 2UniProt
Febrile seizures, familial, 8UniProt
Generalized epilepsy with febrile seizures plus 3UniProt
Pathogenic Variants127
NM_198904.4(GABRG2):c.769G>A (p.Gly257Arg)Pathogenic
Self-limited epilepsy with centrotemporal spikes|EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2;Febrile seizures, familial, 8|not provided|Nonpapillary renal cell carcinoma
โ˜…โ˜…โ˜†โ˜†2026โ†’ Residue 257
NM_198904.4(GABRG2):c.269C>T (p.Thr90Met)Pathogenic
Autosomal dominant nocturnal frontal lobe epilepsy|Febrile seizures, familial, 8|EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2;Febrile seizures, familial, 8|not provided|Febrile seizures, familial, 8;Developmental and epileptic encephalopathy, 74;Generalized epilepsy with febrile seizures plus 3|Developmental and epileptic encephalopathy, 74
โ˜…โ˜…โ˜†โ˜†2025โ†’ Residue 90
NM_198904.4(GABRG2):c.244C>T (p.Arg82Trp)Pathogenic
EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2;Febrile seizures, familial, 8|Inborn genetic diseases
โ˜…โ˜…โ˜†โ˜†2025โ†’ Residue 82
NM_198904.4(GABRG2):c.316G>A (p.Ala106Thr)Pathogenic
not provided|EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2;Febrile seizures, familial, 8|Developmental and epileptic encephalopathy, 74|Inborn genetic diseases|Febrile seizures, familial, 8;Developmental and epileptic encephalopathy, 74
โ˜…โ˜…โ˜†โ˜†2025โ†’ Residue 106
NM_198904.4(GABRG2):c.670C>T (p.Arg224Ter)Pathogenic
not provided|EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2;Febrile seizures, familial, 8|Inborn genetic diseases|Febrile seizures, familial, 8|Seizure
โ˜…โ˜…โ˜†โ˜†2025โ†’ Residue 224
NM_198904.4(GABRG2):c.1310G>A (p.Trp437Ter)Pathogenic
not provided|EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2;Febrile seizures, familial, 8
โ˜…โ˜…โ˜†โ˜†2025โ†’ Residue 437
NM_198904.4(GABRG2):c.992A>G (p.Tyr331Cys)Pathogenic
not provided|EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2;Febrile seizures, familial, 8|Inborn genetic diseases
โ˜…โ˜…โ˜†โ˜†2025โ†’ Residue 331
NM_198904.4(GABRG2):c.974C>T (p.Ser325Leu)Pathogenic
Febrile seizures, familial, 8;EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2|not provided
โ˜…โ˜…โ˜†โ˜†2025โ†’ Residue 325
NM_198904.4(GABRG2):c.212_215del (p.Asn71fs)Pathogenic
Inborn genetic diseases|Febrile seizures, familial, 8
โ˜…โ˜…โ˜†โ˜†2025โ†’ Residue 71
NM_198904.4(GABRG2):c.501C>A (p.Asn167Lys)Pathogenic
EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2;Febrile seizures, familial, 8|not provided
โ˜…โ˜…โ˜†โ˜†2025โ†’ Residue 167
NM_198904.4(GABRG2):c.967C>T (p.Arg323Trp)Pathogenic
EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2;Febrile seizures, familial, 8|Intellectual disability|Febrile seizures, familial, 8|Febrile seizures, familial, 8;Developmental and epileptic encephalopathy, 74|not provided
โ˜…โ˜…โ˜†โ˜†2025โ†’ Residue 323
NM_198904.4(GABRG2):c.968G>A (p.Arg323Gln)Pathogenic
Generalized epilepsy with febrile seizures plus 3|not provided|Self-limited epilepsy with centrotemporal spikes|Febrile seizures, familial, 8;EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2|Developmental and epileptic encephalopathy, 74|Inborn genetic diseases
โ˜…โ˜…โ˜†โ˜†2025โ†’ Residue 323
NM_198904.4(GABRG2):c.245G>A (p.Arg82Gln)Pathogenic
EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2|Febrile seizures, familial, 8|not provided|EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2;Febrile seizures, familial, 8|Epilepsy
โ˜…โ˜…โ˜†โ˜†2025โ†’ Residue 82
NM_198904.4(GABRG2):c.406C>T (p.Arg136Ter)Pathogenic
Lennox-Gastaut syndrome|EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2;Febrile seizures, familial, 8
โ˜…โ˜…โ˜†โ˜†2025โ†’ Residue 136
NM_198904.4(GABRG2):c.259+1G>APathogenic
Inborn genetic diseases|Generalized epilepsy with febrile seizures plus 3;Febrile seizures, familial, 8;Developmental and epileptic encephalopathy, 74|Febrile seizures, familial, 8;EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2
โ˜…โ˜…โ˜†โ˜†2025
NM_198904.4(GABRG2):c.529C>T (p.Arg177Ter)Pathogenic
EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2;Febrile seizures, familial, 8|Developmental and epileptic encephalopathy, 74|not provided
โ˜…โ˜…โ˜†โ˜†2025โ†’ Residue 177
NM_198904.4(GABRG2):c.452_455del (p.Phe151fs)Pathogenic
not provided|EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2;Febrile seizures, familial, 8
โ˜…โ˜…โ˜†โ˜†2025โ†’ Residue 151
NM_198904.4(GABRG2):c.1217_1218del (p.Gln406fs)Pathogenic
not provided|EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2;Febrile seizures, familial, 8|Febrile seizures, familial, 8
โ˜…โ˜…โ˜†โ˜†2025โ†’ Residue 406
NM_198904.4(GABRG2):c.892A>T (p.Lys298Ter)Pathogenic
Inborn genetic diseases|Developmental and epileptic encephalopathy, 74
โ˜…โ˜…โ˜†โ˜†2025โ†’ Residue 298
NM_198904.4(GABRG2):c.859G>A (p.Val287Ile)Likely pathogenic
EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2;Febrile seizures, familial, 8|Seizure
โ˜…โ˜…โ˜†โ˜†2024โ†’ Residue 287
View on ClinVar โ†—
Drug Targets74
ABP-700Phase II
GABA-A receptor; anion channel agonist
ACAMPROSATEApproved
Glutamate [NMDA] receptor antagonist
alcohol dependence
ACAMPROSATE CALCIUMApproved
Glutamate [NMDA] receptor antagonist
alcohol dependence
ADIPIPLONPhase II
GABA-A receptor; anion channel partial agonist
sleep-wake disorder
ALPRAZOLAMApproved
GABA-A receptor; anion channel positive allosteric modulator
panic disorder
BREXANOLONEApproved
GABA-A receptor; anion channel positive allosteric modulator
BUTABARBITALApproved
GABA-A receptor; anion channel positive allosteric modulator
insomnia
BUTALBITALApproved
GABA-A receptor; anion channel positive allosteric modulator
migraine disorder
CENOBAMATEApproved
Sodium channel alpha subunit inhibitor
Seizure
CHLORDIAZEPOXIDEApproved
GABA-A receptor; anion channel positive allosteric modulator
anxiety disorder
CHLORDIAZEPOXIDE HYDROCHLORIDEApproved
GABA-A receptor; anion channel positive allosteric modulator
CIPEPOFOLPhase III
GABA-A receptor; anion channel agonist
CLOBAZAMApproved
GABA-A receptor; anion channel positive allosteric modulator
CLOMETHIAZOLEPhase III
GABA-A receptor; anion channel positive allosteric modulator
stroke
CLONAZEPAMApproved
GABA-A receptor; anion channel positive allosteric modulator
CLORAZEPATE DIPOTASSIUMApproved
GABA-A receptor; anion channel positive allosteric modulator
CLORAZEPIC ACIDApproved
GABA-A receptor; anion channel positive allosteric modulator
anxiety disorder
CLOTIAZEPAMApproved
GABA-A receptor; anion channel positive allosteric modulator
anxiety disorder
DARIGABATPhase II
GABA-A receptor; anion channel agonist
Chronic pain
DESFLURANEApproved
Potassium channel subfamily K member 10 opener
DIAZEPAMApproved
GABA-A receptor; anion channel positive allosteric modulator
Agitation
ENFLURANEApproved
Potassium channel subfamily K member 10 opener
ESTAZOLAMApproved
GABA-A receptor; anion channel positive allosteric modulator
insomnia
ESZOPICLONEApproved
GABA-A receptor; anion channel positive allosteric modulator
insomnia
ETHCHLORVYNOLApproved
GABA-A receptor; anion channel positive modulator
insomnia
ETIFOXINEApproved
GABA-A receptor; anion channel antagonist
Anxiety
ETOMIDATEApproved
GABA-A receptor; anion channel positive modulator
FLUMAZENILApproved
GABA-A receptor; anion channel allosteric antagonist
FLUNITRAZEPAMApproved
GABA-A receptor; anion channel positive allosteric modulator
insomnia
FLURAZEPAMApproved
GABA-A receptor; anion channel positive allosteric modulator
insomnia
FLURAZEPAM HYDROCHLORIDEApproved
GABA-A receptor; anion channel positive allosteric modulator
GANAXOLONEApproved
GABA-A receptor; anion channel positive allosteric modulator
epilepsy
GLUTETHIMIDEApproved
GABA-A receptor; anion channel positive modulator
insomnia
HALAZEPAMApproved
GABA-A receptor; anion channel positive allosteric modulator
anxiety disorder
HALOTHANEApproved
Potassium channel subfamily K member 10 opener
ISOFLURANEApproved
Potassium channel subfamily K member 2 opener
LORAZEPAMApproved
GABA-A receptor; anion channel positive allosteric modulator
major depressive disorder
MEPROBAMATEApproved
GABA-A receptor; anion channel agonist
anxiety disorder
METHAQUALONEUNKNOWN
GABA-A receptor; anion channel positive allosteric modulator
insomnia
METHAQUALONE HYDROCHLORIDEUNKNOWN
GABA-A receptor; anion channel positive allosteric modulator
METHARBITALApproved
GABA-A receptor; anion channel positive allosteric modulator
epilepsy
METHOHEXITALApproved
GABA-A receptor; anion channel positive allosteric modulator
METHOXYFLURANEApproved
GABA-A receptor; anion channel positive modulator
METHYPRYLONApproved
GABA-A receptor; anion channel positive allosteric modulator
insomnia
MIDAZOLAMApproved
GABA-A receptor; anion channel positive allosteric modulator
epilepsy
MIDAZOLAM HYDROCHLORIDEApproved
GABA-A receptor; anion channel positive allosteric modulator
amnesia
OXAZEPAMApproved
GABA-A receptor; anion channel positive allosteric modulator
Agitation
PADSEVONILPhase II/III
GABA-A receptor; anion channel partial agonist
epilepsy
PAGOCLONEPhase II/III
GABA-A receptor; anion channel positive allosteric modulator
anxiety disorder
PENTOBARBITALApproved
GABA-A receptor; anion channel positive allosteric modulator
insomnia
PENTOBARBITAL SODIUMUNKNOWN
GABA-A receptor; anion channel positive allosteric modulator
PRAZEPAMApproved
GABA-A receptor; anion channel positive allosteric modulator
anxiety disorder
PRIMIDONEApproved
GABA-A receptor; anion channel positive allosteric modulator
epilepsy
PROPOFOLApproved
GABA-A receptor; anion channel positive allosteric modulator
QUAZEPAMApproved
GABA-A receptor; anion channel positive allosteric modulator
REMIMAZOLAMApproved
GABA-A receptor; anion channel positive allosteric modulator
REMIMAZOLAM BESYLATEApproved
GABA-A receptor; anion channel positive allosteric modulator
RESEQUINILPhase II
GABA-A receptor; anion channel inverse agonist
epilepsy
SECOBARBITALApproved
GABA-A receptor; anion channel positive allosteric modulator
SECOBARBITAL SODIUMUNKNOWN
GABA-A receptor; anion channel positive allosteric modulator
SEVOFLURANEApproved
Glycine receptor (alpha-1/beta) positive modulator
TALBUTALApproved
GABA-A receptor; anion channel positive allosteric modulator
Irritability
TEMAZEPAMApproved
GABA-A receptor; anion channel positive allosteric modulator
insomnia
TETRAZEPAMUNKNOWN
GABA-A receptor; anion channel positive allosteric modulator
THIAMYLALApproved
GABA-A receptor; anion channel positive allosteric modulator
THIOPENTALApproved
GABA-A receptor; anion channel positive allosteric modulator
THIOPENTAL SODIUMPhase I
GABA-A receptor; anion channel positive allosteric modulator
amnesia
TOPIRAMATEApproved
Glutamate receptor ionotropic AMPA antagonist
epilepsy
TRIAZOLAMApproved
GABA-A receptor; anion channel positive allosteric modulator
TRICLOFOS SODIUMApproved
GABA-A receptor; anion channel positive modulator
insomnia
ZALEPLONApproved
GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator
ZOLPIDEMApproved
GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator
insomnia
ZOLPIDEM TARTRATEApproved
GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator
insomnia
ZURANOLONEApproved
GABA-A receptor; anion channel positive allosteric modulator
postpartum depression
Related Genes
SCN2AProtein interaction95%KCNQ2Protein interaction93%GPHNProtein interaction93%SLC6A1Protein interaction93%CACNA1HProtein interaction89%CLCN2Protein interaction89%
Tissue Expression6 tissues
Brain
100%
Bone Marrow
0%
Liver
0%
Heart
0%
Ovary
0%
Lung
0%
Gene Interaction Network
Click a node to explore
GABRG2SCN2AKCNQ2GPHNSLC6A1CACNA1HCLCN2
PROTEIN STRUCTURE
Preparing viewerโ€ฆ
PDB9EQG ยท 2.40 ร… ยท EM
View on RCSB โ†—
Constraintโ“˜
LOEUFโ“˜
0.43Moderately Constrained
pLIโ“˜
1.00Intolerant
Observed/Expected LoF0.27 [0.17โ€“0.43]
RankingsWhere GABRG2 stands among ~20K protein-coding genes
  • #2,561of 20,598
    Most Researched172 ยท top quartile
  • #11of 1,025
    FDA-Approved Drug Targets60 ยท top 5%
  • #609of 5,498
    Most Pathogenic Variants127 ยท top quartile
  • #2,289of 17,882
    Most Constrained (LOEUF)0.43 ยท top quartile
Genes detectedGABRG2
Sources retrieved25 papers
Response timeโ€”
๐Ÿ“„ Sources
25โ–ผ
1
Large-scale targeted sequencing identifies risk genes for neurodevelopmental disorders.
PMID: 33004838
Nat Commun ยท 2020
1.00
2
Molecular and clinical descriptions of patients with GABA
PMID: 35718920
Epilepsia ยท 2022
0.90
3
Epilepsy plus blindness in microdeletion of GABRA1 and GABRG2 in mouse and human.
PMID: 37703949
Exp Neurol ยท 2023
0.84
4
Genetic variations in GABA metabolism and epilepsy.
PMID: 35850019
Seizure ยท 2022
0.80
5
Integrative RNA profiling of TBEV-infected neurons and astrocytes reveals potential pathogenic effectors.
PMID: 35685361
Comput Struct Biotechnol J ยท 2022
0.70